FLT3 as a therapeutic target in AML: still challenging after all these years
Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene on chromosome 13q12 have
been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of …
been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of …
Multiparameter flow cytometry in the diagnosis and management of acute leukemia
JM Peters, MQ Ansari - Archives of pathology & laboratory …, 2011 - meridian.allenpress.com
Context—Timely and accurate diagnosis of hematologic malignancies is crucial to
appropriate clinical management. Acute leukemias are a diverse group of malignancies with …
appropriate clinical management. Acute leukemias are a diverse group of malignancies with …
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study
M Terwijn, WLJ van Putten, A Kelder… - Journal of clinical …, 2013 - ascopubs.org
Purpose Half the patients with acute myeloid leukemia (AML) who achieve complete
remission (CR), ultimately relapse. Residual treatment-surviving leukemia is considered …
remission (CR), ultimately relapse. Residual treatment-surviving leukemia is considered …
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in …
T Haferlach, A Kohlmann, L Wieczorek… - Journal of clinical …, 2010 - ascopubs.org
Purpose The Microarray Innovations in Leukemia study assessed the clinical utility of gene
expression profiling as a single test to subtype leukemias into conventional categories of …
expression profiling as a single test to subtype leukemias into conventional categories of …
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
RB Walter, SA Buckley, JM Pagel… - Blood, The Journal …, 2013 - ashpublications.org
Minimal residual disease (MRD) before myeloablative hematopoietic cell transplantation
(HCT) is associated with adverse outcome in acute myeloid leukemia (AML) in first complete …
(HCT) is associated with adverse outcome in acute myeloid leukemia (AML) in first complete …
Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia
SD Freeman, P Virgo, S Couzens… - Journal of Clinical …, 2013 - ascopubs.org
Purpose Older patients with acute myeloid leukemia (AML) have a high relapse rate after
standard chemotherapy. We investigated whether measuring chemotherapy sensitivity by …
standard chemotherapy. We investigated whether measuring chemotherapy sensitivity by …
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U Platzbecker, M Wermke, J Radke, U Oelschlaegel… - Leukemia, 2012 - nature.com
This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined
by a sensitive donor chimerism analysis of CD34+ blood cells to pre-empt relapse in …
by a sensitive donor chimerism analysis of CD34+ blood cells to pre-empt relapse in …
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation …
Purpose Allogeneic hematopoietic cell transplantation (HCT) benefits many patients with
acute myeloid leukemia (AML) in first remission. Hitherto, little attention has been given to …
acute myeloid leukemia (AML) in first remission. Hitherto, little attention has been given to …
Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell …
CH Yan, DH Liu, KY Liu, LP Xu, YR Liu… - Blood, The Journal …, 2012 - ashpublications.org
We studied the impact of risk stratification–directed interventions for minimal residual
disease (MRD) on relapse and disease-free survival (DFS) prospectively in 814 subjects …
disease (MRD) on relapse and disease-free survival (DFS) prospectively in 814 subjects …
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in …
MH Gilleece, M Labopin, I Yakoub‐Agha… - American journal of …, 2018 - Wiley Online Library
Patients with acute myeloid leukemia (AML) in morphological first complete remission (CR1)
pre‐allogeneic hematopoietic cell transplantation (HCT) may have measurable residual …
pre‐allogeneic hematopoietic cell transplantation (HCT) may have measurable residual …